Results 221 to 230 of about 63,889 (276)

Case Report: Successful Treatment With Apremilast of SAPHO Syndrome and Refractory Pain. [PDF]

Int J Rheum Dis
Pickering ME, Blanchard L, Malochet-Guinamand S, Tournadre A, Chanchou M.   +4 more
europepmc   +1 more source

Cytokine‐Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies—A Narrative Review

Health Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims Long COVID, also known as post‐acute sequelae of SARS‐CoV‐2 infection (PASC), is a multisystem condition characterized by persistent symptoms that continue beyond the acute phase of infection. Growing evidence indicates that sustained immune dysregulation involving cytokine‐mediated inflammation, complement activation ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Delayed diagnosis of primary cutaneous histoplasmosis in a patient receiving tumour necrosis factor alpha inhibitor therapy. [PDF]

BMJ Case Rep
Kalangi H, Goyal SK, El Soufi H.
europepmc   +1 more source

Combination Treatment of IL‐17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Background Psoriatic arthritis (PsA) is a chronic inflammatory disease with complex pathophysiology. Despite advancements in biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), treatment responses remain suboptimal for many patients.
Mengduan Pang, Ling Li, Qi Zhang, Min Zhao   +3 more
wiley   +1 more source

Infantile Onset Haploinsufficiency of A20 Treated by Infliximab, a Case Report and Brief Review of Literature. [PDF]

Int Med Case Rep J
Salehzadeh F, Babazadeh Khoei F.
europepmc   +1 more source

Population Pharmacokinetics and Dose De‐Escalation Regimens of Subcutaneous Vedolizumab in Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background Vedolizumab is a therapeutic antibody approved for the treatment of Crohn's disease and ulcerative colitis. The population pharmacokinetics (popPK) of intravenous (IV) administered vedolizumab have been described, but remain to be defined for subcutaneous (SC) administration.
S. I. Anjie, N. Vreman, K. B. Gecse, M. Löwenberg, G. R. D'Haens, R. A. A. Mathôt   +5 more
wiley   +1 more source

Esperienze su Infliximab

, 2009
G. Altomare
core   +2 more sources

Mechanisms of therapeutic antibodies immunogenicity: infliximab oligomeric aggregates increase T-cell response and uptake by dendritic cells involving mannose-sensitive receptor CD206. [PDF]

Front Immunol
Lteif M, Nabhan M, Tardif C, Smadja C, Mata-Orozco J, Hua S, Maillère B, Pallardy M, Turbica I.   +8 more
europepmc   +1 more source

Auricular Relapsing Polychondritis in a Patient With Crohn's Disease: A Case Report. [PDF]

Sisli Etfal Hastan Tip Bul
Ulas BN, Cagdas BM, Yigit O, Hatemi I.
europepmc   +1 more source

Autoinflammation with infantile enterocolitis associated with a novel CARD domain mutation in <i>NLRC4</i>: a case report and literature review. [PDF]

Front Pediatr
Mao Y, Xie Y.
europepmc   +1 more source